

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Attorney Docket No. 056291-5283		Application No. 10/578,663	
PTO Form 1449 December 4, 2008				Applicants: HENNEQUIN et al.			
				Filing Date: January 17, 2007		Group Art Unit: 1624	
U.S. PATENT DOCUMENTS							
Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date	
	1. US 2003/0186995	October 2, 2003	Kath et al.				
	2. US 2004/0048880	March 11, 2004	Himmelsbach et al.				
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./							
OTHER PATENT DOCUMENTS							
	Document No.	Date	Country	Names			
	3. CA 2476008	October 9, 2003	Canada	XXXXXXXXXXXXXXXXXXXX			
	4. CA 2543649	May 12, 2005	Canada	Boehringer Ingelheim			
	5. WO 01/21596	March 29, 2001	WIPO	Astrazeneca Ltd.			
	6. WO 2004/046101	June 3, 2004	WIPO	Array Biopharma Inc.			
	7. WO 2004/006846	January 22, 2004	WIPO	Ex Elixix Inc.			
	8. WO 2005/013998	February 17, 2005	WIPO	Astrazeneca Ltd.			
	9. WO 2005/041973	May 12, 2005	WIPO	Boehringer Ingelheim Co.			
	10. WO 2005/097134	October 20, 2005	WIPO	The Scripps Res. Inst.			
ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./							
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
	11.	Ballard et al. "Developing a small molecule erbB2 inhibitor: challenges with optimising DMPK properties" Poster - Presented at DMDG Cambridge (February 6, 2008).					
	12.	Ballard et al. "Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase" Bioorg Med Chem Lett. 17(22):6326-6329 (2007).					
	13.	Barlaam et al. "A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase" Bioorganic & Medicinal Chemistry Letters 18(2):674-678 (2008).					
	14.	Barlaam et al. "Indazolylamino/Anilinoquinazolines Bearing a C-5 substitution as erbB2 kinase inhibitors: Structure-activity relationships and identification of a candidate drug" at AACR in 2007.					
	15.	Barlaam et al. "Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase" Bioorganic & Medicinal Chemistry Letters 18(6):1799-1803 (2008).					
	16.	Barlaam et al. "Indazolylamino/Anilinoquinazolines Bearing a C-5 Substitution As erbB2 Kinase Inhibitors: Structure-Activity Relationships and Identification of a Candidate Drug" Poster number P044, presented at XXth International Symposium on Medicinal Chemistry (EFMC-ISM 2008), Vienna, Austria, August 31 - September 4, 2008.					
	17.	Cockerill et al. "Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFR and c-erbB-2" Bioorganic & Medicinal Chemistry Letters 11(11):1401-1405 (2001).					
	18.	Ducray et al. "Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors" Bioorganic & Medicinal Chemistry Letters 18(3):959-962 (2008).					
	19.	Gaul et al. "Discovery and Biological Evaluation of Potent Dual ErbB-2/EGFR Tyrosine Kinase Inhibitors: 6-Thiazolylquinazolines" Bioorganic & Medicinal Chemistry Letters 13(4):637-640 (2003).					
	20.	Harris et al. "Systematic variation of a key quinazoline core" Presented at the XXII European Colloquium on Heterocyclic Chemistry (XXII ECHC-2006) Bari, Italy, September 2-6, 2006.					
	21.	Hennequin et al. "N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yl)oxyquinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor" J Med Chem. 49(22):6465-6488 (2006).					
Examiner	/Tamthorn Truong/		Date Considered		04/09/2009		
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

